search
Back to results

TReAtment With Concurrent Exercise in Patients With Resistant Major Depression (TRACE-RMD)

Primary Purpose

Resistant Depression, Treatment

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Concurrent training
Sponsored by
University of the Basque Country (UPV/EHU)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Resistant Depression, Treatment focused on measuring Depression, Physical Exercise, Low-intensity Interval Training, Resistance Training

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Depression major disorder.
  • 2 or more antdepressives resistant a treatment.
  • Consent informed signed

Exclusion Criteria:

  • Schizophrenia or other disorders.
  • Suicide risk.
  • Unstable medic illness or unsuitable controlled.
  • Disorder for use of active substances.
  • Comorbidity with other psychiatric pathologies.
  • Montreal Cognitive Assessment <26/30, cognitive deterioration.
  • Incapacity for realizing physical exercise because of osteoarticular, cardiovascular, or metabolic difficulty.

Sites / Locations

  • Basque Country UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention group

Arm Description

Intervention group: In the physical exercise session will carry out a concurrent training in four parts, low- intensity interval training in a bicycle, resistance circuit training, ow- intensity interval training in a bicycle, and CORE exercises.

Outcomes

Primary Outcome Measures

Montgomery-Asberg Depressión Rating Scale (MADRS)
Ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Cardiorespiratory fitness
Cardiorespiratory fitness evaluation measured by cardiopulmonary exercise test. Maximu oxygen uptake measured in mL/kg/min or L/min is the gold standard variable.

Secondary Outcome Measures

Clinical Global Impression Scale (CGI)
The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Its 3 items assess, 1) Severity of Illness (CGI-S), 2) Global Improvement (CGI-I), and 3) Efficacy Index (CGI-E, which is a measure of treatment effect and side effects specific to drugs that were administered).
Sheehan Disability Scale (SDS)
five-item, self-rated questionnaire designed to measure the extent to which a patient's disability due to an illness or health problem interferes with work/school, social life/leisure activities, and family life/home responsibilities. Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.
Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9)
To measure patients' satisfaction with medication

Full Information

First Posted
November 1, 2021
Last Updated
November 24, 2021
Sponsor
University of the Basque Country (UPV/EHU)
Collaborators
Red Salud Mental Araba
search

1. Study Identification

Unique Protocol Identification Number
NCT05136027
Brief Title
TReAtment With Concurrent Exercise in Patients With Resistant Major Depression
Acronym
TRACE-RMD
Official Title
Effects of Treatment With Concurrent Exercise in Patients With Resistant Major Depression
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 30, 2022 (Anticipated)
Primary Completion Date
June 30, 2022 (Anticipated)
Study Completion Date
July 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of the Basque Country (UPV/EHU)
Collaborators
Red Salud Mental Araba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim is to apply an exercise program to study symptomatic and physical changes, as well as to evaluate the improvement in functionality in a resistant depression unit. Sample: 20 patients with the resistant major depressive disorder who will undergo an exercise program. Before and after 12 weeks of intervention, the participants will be assessed with clinical, physical, physiological, biochemical, and functional variables. During 3 months the exercise program will be implemented 2 days per week. It is expected to find an improvement in mood and functionality, as well as changes in physical areas such as blood pressure or body mass index, which are considered predictive factors of cardiovascular disease.
Detailed Description
The presence of major depressive disorder (MDD) in today's society is worryingly high. Specifically, the prevalence-year prevalence of MDD in Spain is 3.9% and lifetime prevalence is 10.5%. The lifetime prevalence for men is 6.29% and 14.47% for women in Spain according to the ESEMED-Spain study. Although there is no explicit international consensus, the medical literature and research define treatment-resistant depression (TRD) as any MDD that does not respond to two trials of treatment antidepressant treatment at adequate doses and for an adequate duration of time. MDD is the leading cause of years lived with disability worldwide, accounting for 11.9%. It has been estimated that during the year 2020 it could be second only to ischemic heart disease in disability-adjusted life years lost. Given this bleak scenario, different non-pharmacological strategies have been considered as possible complementary treatments to pharmacological treatment to help improve the prognosis of MDD and remission rates, such as exercise and electroconvulsive therapy. Sedentary lifestyles are a very common feature in the severely mentally disordered population. One of the causes for this to occur is that people with MDD have very little confidence in their ability to exercise and lack the necessary social support. This inactivity together with other modifiable risk factors such as tobacco use, high blood pressure, and overweight/obesity, in addition to the side effects of pharmacological treatments contributes to the appearance of different diseases, as well as decreased life expectancy and quality of life. TDM can act as a cause or as a repercussion of physical inactivity. It has been recognized for several years that the performance of regular exercise is cardioprotective, decreasing the incidence of cardiovascular diseases such as arterial hypertension, coronary artery disease, type 2 diabetes, and atherosclerosis. In addition to being cardioprotective, exercise has shown a positive association with psychological well-being and therapeutic benefits in older people with depressive disorder, depressive symptoms in patients with Alzheimer's disease and MDD. Although there is still some controversy about the intensity and frequency of exercise, and the duration of the exercise program, the recommendations were the adoption of a moderate-intensity exercise program of at least 30 minutes on most days of the week, for 10-12 weeks. In the latest World Health Organization guidelines on physical activity (PA) and sedentary habits, for the improvement of quality of life in adults with TMD the general recommendations do not differ from the general population, i.e., people should accumulate throughout the week a minimum of 150-300 minutes of moderate aerobic PA or a minimum of 75-150 minutes of vigorous PA, or an equivalent combination of both in order to obtain notable health benefits. Also, in order to achieve additional health benefits, the participants should perform two days a week of moderate or higher intensity muscle-strengthening activities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Depression, Treatment
Keywords
Depression, Physical Exercise, Low-intensity Interval Training, Resistance Training

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Physical exercise group
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Intervention group: In the physical exercise session will carry out a concurrent training in four parts, low- intensity interval training in a bicycle, resistance circuit training, ow- intensity interval training in a bicycle, and CORE exercises.
Intervention Type
Other
Intervention Name(s)
Concurrent training
Intervention Description
Low intensity interval training and resistance exercise
Primary Outcome Measure Information:
Title
Montgomery-Asberg Depressión Rating Scale (MADRS)
Description
Ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Time Frame
12 weeks
Title
Cardiorespiratory fitness
Description
Cardiorespiratory fitness evaluation measured by cardiopulmonary exercise test. Maximu oxygen uptake measured in mL/kg/min or L/min is the gold standard variable.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Clinical Global Impression Scale (CGI)
Description
The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Its 3 items assess, 1) Severity of Illness (CGI-S), 2) Global Improvement (CGI-I), and 3) Efficacy Index (CGI-E, which is a measure of treatment effect and side effects specific to drugs that were administered).
Time Frame
12 weeks
Title
Sheehan Disability Scale (SDS)
Description
five-item, self-rated questionnaire designed to measure the extent to which a patient's disability due to an illness or health problem interferes with work/school, social life/leisure activities, and family life/home responsibilities. Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.
Time Frame
12 weeks
Title
Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9)
Description
To measure patients' satisfaction with medication
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Depression major disorder. 2 or more antdepressives resistant a treatment. Consent informed signed Exclusion Criteria: Schizophrenia or other disorders. Suicide risk. Unstable medic illness or unsuitable controlled. Disorder for use of active substances. Comorbidity with other psychiatric pathologies. Montreal Cognitive Assessment <26/30, cognitive deterioration. Incapacity for realizing physical exercise because of osteoarticular, cardiovascular, or metabolic difficulty.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Maldonado-Martin, PhD
Phone
34945013534
Email
sara.maldonado@ehu.eus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
NAGORE IRIARTE-YOLLER, MD
Organizational Affiliation
PSYCHIATRIC HOSPITAL OF ÁLAVA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Basque Country University
City
Vitoria Gasteiz
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Maldonado-Martín
Phone
34945013534
Email
sara.maldonado@ehu.eus

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
A protocol paper will be written once the clinical trials identification number will be defined
IPD Sharing Time Frame
indefinite period
IPD Sharing Access Criteria
no criteria

Learn more about this trial

TReAtment With Concurrent Exercise in Patients With Resistant Major Depression

We'll reach out to this number within 24 hrs